地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗乳腺癌化疗后粒细胞减少价值研究
|
摘要
目的:探究地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗乳腺癌化疗后粒细胞减少价值。方法:114例乳腺癌化疗后粒细胞减少患者,采取随机数字表法平均分为观察组以及对照组,对照组所有患者(57例)均采取聚乙二醇化重组人粒细胞刺激因子治疗,观察组所有患者(57例)则采取地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗,对比两组患者临床治疗效果、治疗前后患者症状积分、患者发热持续时间及粒细胞缺乏持续时间、治疗过程中不良反应情况及患者对治疗满意程度。结果:观察组患者治疗总有效率(98.25%)高于对照组(87.72%),P<0.05,差异具有统计学意义;观察组患者治疗前症状积分为(7.45±1.04)分,对照组症状积分为(7.43±1.11)分,两组患者治疗前症状积分相当,P>0.05,差异无统计学意义,治疗后观察组积分为(2.33±0.46)分,对照组积分为(3.89±0.48)分,经治疗后各组患者症状积分均一定程度下降,患者症状均改善,观察组改善优于对照组,P<0.05,差异具有统计学意义;观察组患者治疗后发热持续时间为(6.34±1.32)d,短于对照组(10.24±1.11)d,粒细胞缺乏持续时间为(5.11±1.01)d,短于对照组(8.42±1.06)d,P<0.05,差异具有统计学意义;观察组治疗过程中总不良反应发生率(1.75%)与对照组(3.51%)相当,两组不良反应发生率均较低,P>0.05,差异无统计学意义;观察组患者治疗总满意率(96.49%)高于对照组(85.96%),P<0.05,差异具有统计学意义。结论:地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗乳腺癌化疗后粒细胞减少效果良好,患者粒细胞减少症状明显改善,且患者恢复快,满意率高,值得临床广泛推广以及应用。
Objective:To explore the value of granulocytes in the treatment of breast cancer chemoradiotherapy by using the combination of Diyu Shengbai Tablets and polyethylene glycol recombinant human granulocyte stimulating factor.Methods:114 cases of breast cancer after chemotherapy granulocytopenia patients as the research objects, according to a random number table method,were divided into observation group and control group. The control group's patients(57 cases) were treated with polyethylene glycol and recombinant human granulocyte stimulating factor. The observation group's patients(57 cases) tookDiyu Shengbai Tablets combined with polyethylene glycol recombinant human granulocyte stimulating factor treatment. We compared two groups' clinical therapeutic effect, duration of symptoms integral before and after treatment, patients fever and granulocyte lack of duration, treatment process and adverse reaction.Results:The total effective rate(98.25%) in the observation group was higher than that in the control group(87.72%)(P<0.05) and the difference was statistically significant. Observation group's symptoms integral was(7.45±1.04) points and the control group'swas(7.43±1.11) points. Two groups' symptoms integral before treatment had no statistically significant(P>0.05). The observation group's after treatmentsymptoms integral was(2.33±0.46) points and the control group's was(3.89±0.48) points after treatment. After treatment both groups' symptoms integral decreased to a certain degree and patients' symptoms were improved. The observation group's improvementwas better than that of the control group(P<0.05) and the difference was statistically significant. The observation group's fever duration(6.34±1.32)d was shorter than the control group's(10.24±1.11)d and granulocyte lack duration(5.11±1.01)d was shorter than the control group's(8.42±1.06)d after treatment(P<0.05) and the difference was statistically significant. The incidence of total adverse reactions(1.75%) was similar to that in the control group(3.51%) and the incidence of adverse reactions was lower in both groupswith no statistically significant difference(P>0.05). The total satisfaction rate of patients in the observation group(96.49%) was higher than that in the control group(85.96%)(P<0.05) and the difference was statistically significant.Conclusion:Diyu Shengbai Tablets combined with polyethylene glycolrecombinant human granulocyte stimulating factor for breast cancer after chemotherapy granulocytopenia has goodeffect. The granulocytopenia in patients was improved with fastrecover, high satisfaction rate, worthy of clinical application and spread.
Objective:To explore the value of granulocytes in the treatment of breast cancer chemoradiotherapy by using the combination of Diyu Shengbai Tablets and polyethylene glycol recombinant human granulocyte stimulating factor.Methods:114 cases of breast cancer after chemotherapy granulocytopenia patients as the research objects, according to a random number table method,were divided into observation group and control group. The control group's patients(57 cases) were treated with polyethylene glycol and recombinant human granulocyte stimulating factor. The observation group's patients(57 cases) tookDiyu Shengbai Tablets combined with polyethylene glycol recombinant human granulocyte stimulating factor treatment. We compared two groups' clinical therapeutic effect, duration of symptoms integral before and after treatment, patients fever and granulocyte lack of duration, treatment process and adverse reaction.Results:The total effective rate(98.25%) in the observation group was higher than that in the control group(87.72%)(P<0.05) and the difference was statistically significant. Observation group's symptoms integral was(7.45±1.04) points and the control group'swas(7.43±1.11) points. Two groups' symptoms integral before treatment had no statistically significant(P>0.05). The observation group's after treatmentsymptoms integral was(2.33±0.46) points and the control group's was(3.89±0.48) points after treatment. After treatment both groups' symptoms integral decreased to a certain degree and patients' symptoms were improved. The observation group's improvementwas better than that of the control group(P<0.05) and the difference was statistically significant. The observation group's fever duration(6.34±1.32)d was shorter than the control group's(10.24±1.11)d and granulocyte lack duration(5.11±1.01)d was shorter than the control group's(8.42±1.06)d after treatment(P<0.05) and the difference was statistically significant. The incidence of total adverse reactions(1.75%) was similar to that in the control group(3.51%) and the incidence of adverse reactions was lower in both groupswith no statistically significant difference(P>0.05). The total satisfaction rate of patients in the observation group(96.49%) was higher than that in the control group(85.96%)(P<0.05) and the difference was statistically significant.Conclusion:Diyu Shengbai Tablets combined with polyethylene glycolrecombinant human granulocyte stimulating factor for breast cancer after chemotherapy granulocytopenia has goodeffect. The granulocytopenia in patients was improved with fastrecover, high satisfaction rate, worthy of clinical application and spread.
引文
[1] 罗教秀,储兵,曹晓珊,等.免疫组化法与双色银染原位杂交法用于乳腺癌HER-2检测诊断中的应用价值分析[J].标记免疫分析与临床,2017,24(6):610-613.
[2] 段永强,夏淑平,吴敏,等.TPINP和ICTP检测及SPECT和CT显像在乳腺癌骨转移中的应用[J].标记免疫分析与临床,2017,24(8):867-869,879.
[3] 李华民.EGFR、Ki67在三阴性与非三阴性乳腺癌中的表达及其与TNBC病理特征的相关性[J].实用癌症杂志,2017,32(11):1759-1762.
[4] 董涵之,彭志强,邱志敏,等.76例乳腺癌脑转移患者临床特征及预后因素分析[J].实用癌症杂志,2017,32(10):1624-1627.
[5] 谢明瑞,李雨遥,赵昌涛,等.培美曲塞联合环磷酰胺治疗复发转移性乳腺癌的疗效观察[J].现代药物与临床,2017,32(11):2216-2220.
[6] 战祥毅,隋鑫,王文萍,等.中医治疗乳腺癌术后上肢淋巴水肿研究进展[J].临床军医杂志,2017,45(2):216-220.
[7] 刘永明,刘兆喆,谢晓冬,等.中药外敷联合淋巴引流技术治疗乳腺癌术后上肢水肿疗效观察[J].创伤与急危重病医学,2017,5(2):72-75.
[8] 杨卉,许文林,苏兆亮,等.肺腺癌转移相关转录本1在乳腺癌患者血浆中的表达及临床意义[J].江苏大学学报(医学版),2018,28(1):51-55,91.
[9] 李建梅,孙静宜,赵月,等.替吉奥联合多西他赛治疗转移性乳腺癌的疗效及对血清HER2、VEGF及CA72-4水平的影响[J].空军医学杂志,2017,33(1):33-35,43.
[10] 远丽芳,陈俊林,王津京,等.乳腺癌化疗后中性粒细胞减少性发热的临床观察[J].北京医学,2017,39(11):1138-1141.
[11] 黄景慧,尤冬山,陈欣,等.晚期乳腺癌患者行FAC方案化疗对体内氧化应激水平的影响[J].疑难病杂志,2017,16(4):377-380,384.
[12] 罗恩茜,倪青.乳腺癌不同方案新辅助化疗后对粒细胞减少的影响及处理[J].重庆医学,2018,47(7):971-974.
[13] 张彦武,吕以东,牛耀东,等.卡培他滨联合顺铂与卡培他滨联合多西他赛治疗三阴性复发转移性乳腺癌的临床研究[J].中国现代医学杂志,2017,27(10):66-70.
[14] 黄世杰.CDK4/6抑制剂abemaciclibⅢ期临床治疗晚期或复发乳腺癌试验达到主终点[J].国际药学研究杂志,2017,44(4):347.
[15] 李颖,姜达,吴圆圆,等.替吉奥和卡培他滨治疗进展期乳腺癌的多中心临床研究[J].中华肿瘤杂志,2017,39(8):607-612.
[16] 徐敏,曹德东,戈伟,等.热疗联合化疗治疗晚期或胸壁复发乳腺癌疗效及安全性的Meta分析[J].中国医药导报,2017,14(26):4-8,20.
[17] 王丰莲,楚爱景.康莱特注射液联合化疗治疗乳腺癌患者的疗效与安全性观察[J].内科,2018,13(1):90-92,116.
[18] 陈雪姣,周凤杰,赵伟锋,等.紫杉醇脂质体用于乳腺癌新辅助化疗的疗效与安全性[J].中国医院用药评价与分析,2017,17(8):1058-1060.
[19] 田柳.华蟾素胶囊辅助治疗晚期乳腺癌疗效及耐受性观察[J].西南国防医药,2017,27(11):1173-1175.
[20] 邓爽,冯国斌,徐久东,等.华蟾素胶囊联合含卡培他滨基础方案治疗晚期乳腺癌疗效及耐受性观察[J].药学与临床研究,2017,25(5):439-443.
[21] 马传栋,步晓秋,王忠锐,等.含脂质体阿霉素方案在乳腺癌术后辅助化疗中的安全性评价[J].临床肿瘤学杂志,2017,22(7):642-645.
[22] 律慧敏,张梦玮,牛李敏,等.国产多西他赛单药治疗晚期乳腺癌的疗效及安全性[J].山东大学学报(医学版),2018,56(1):45-49.
[23] 沈刚,沈文香.多西他赛联合噻替哌治疗对乳腺癌组织中上皮间质转化分子标志物及Beclin 1表达的影响[J].中国妇幼保健,2017,32(18):4536-4539.
[24] 吴旦平,张红丹,汪波,等.PEG-rhG-CSF注射液对乳腺癌术后化疗致中性粒细胞减少的防治效果[J].重庆医学,2018,47(4):546-548.
[25] 陈喜梅,蔡亚飞,吕转,等.重组人粒细胞集落刺激因子在乳腺癌化疗后应用的临床分析[J].中国实用医刊,2017,44(10):42-45.
[26] 石远凯,许建萍,吴昌平,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少症的多中心上市后临床研究[J].中国肿瘤临床,2017,44(14):679-684.
[27] 徐兵河,田富国,喻璟瑞,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅲ期临床研究[J].中华肿瘤杂志,2016,38(1):23-27.
[28] 邓建良,姚强,张云雷,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞计数减少的临床观察[J].临床内科杂志,2017,34(4):268-270.
[29] 董莉.地榆升白片治疗儿童感染相关粒细胞减少症疗效观察[J].实用中医药杂志,2016,32(10):1010-1011.
[30] 陈君,汪川.地榆升白片治疗儿童中性粒细胞减少症180例疗效观察[J].中国社区医师,2017,33(29):77-79.
[31] 赵泽丰,何希瑞,张强,等.地榆升白片治疗肿瘤化疗后引起的白细胞减少Meta分析[J].西北药学杂志,2017,32(5):648-652.
[32] 刘纯一,胡新彦,徐立霞,等.地榆升白片联合重组人粒细胞刺激因子治疗癌症相关性乏力的临床分析[J].中国生化药物杂志,2015(3):98-99.
[2] 段永强,夏淑平,吴敏,等.TPINP和ICTP检测及SPECT和CT显像在乳腺癌骨转移中的应用[J].标记免疫分析与临床,2017,24(8):867-869,879.
[3] 李华民.EGFR、Ki67在三阴性与非三阴性乳腺癌中的表达及其与TNBC病理特征的相关性[J].实用癌症杂志,2017,32(11):1759-1762.
[4] 董涵之,彭志强,邱志敏,等.76例乳腺癌脑转移患者临床特征及预后因素分析[J].实用癌症杂志,2017,32(10):1624-1627.
[5] 谢明瑞,李雨遥,赵昌涛,等.培美曲塞联合环磷酰胺治疗复发转移性乳腺癌的疗效观察[J].现代药物与临床,2017,32(11):2216-2220.
[6] 战祥毅,隋鑫,王文萍,等.中医治疗乳腺癌术后上肢淋巴水肿研究进展[J].临床军医杂志,2017,45(2):216-220.
[7] 刘永明,刘兆喆,谢晓冬,等.中药外敷联合淋巴引流技术治疗乳腺癌术后上肢水肿疗效观察[J].创伤与急危重病医学,2017,5(2):72-75.
[8] 杨卉,许文林,苏兆亮,等.肺腺癌转移相关转录本1在乳腺癌患者血浆中的表达及临床意义[J].江苏大学学报(医学版),2018,28(1):51-55,91.
[9] 李建梅,孙静宜,赵月,等.替吉奥联合多西他赛治疗转移性乳腺癌的疗效及对血清HER2、VEGF及CA72-4水平的影响[J].空军医学杂志,2017,33(1):33-35,43.
[10] 远丽芳,陈俊林,王津京,等.乳腺癌化疗后中性粒细胞减少性发热的临床观察[J].北京医学,2017,39(11):1138-1141.
[11] 黄景慧,尤冬山,陈欣,等.晚期乳腺癌患者行FAC方案化疗对体内氧化应激水平的影响[J].疑难病杂志,2017,16(4):377-380,384.
[12] 罗恩茜,倪青.乳腺癌不同方案新辅助化疗后对粒细胞减少的影响及处理[J].重庆医学,2018,47(7):971-974.
[13] 张彦武,吕以东,牛耀东,等.卡培他滨联合顺铂与卡培他滨联合多西他赛治疗三阴性复发转移性乳腺癌的临床研究[J].中国现代医学杂志,2017,27(10):66-70.
[14] 黄世杰.CDK4/6抑制剂abemaciclibⅢ期临床治疗晚期或复发乳腺癌试验达到主终点[J].国际药学研究杂志,2017,44(4):347.
[15] 李颖,姜达,吴圆圆,等.替吉奥和卡培他滨治疗进展期乳腺癌的多中心临床研究[J].中华肿瘤杂志,2017,39(8):607-612.
[16] 徐敏,曹德东,戈伟,等.热疗联合化疗治疗晚期或胸壁复发乳腺癌疗效及安全性的Meta分析[J].中国医药导报,2017,14(26):4-8,20.
[17] 王丰莲,楚爱景.康莱特注射液联合化疗治疗乳腺癌患者的疗效与安全性观察[J].内科,2018,13(1):90-92,116.
[18] 陈雪姣,周凤杰,赵伟锋,等.紫杉醇脂质体用于乳腺癌新辅助化疗的疗效与安全性[J].中国医院用药评价与分析,2017,17(8):1058-1060.
[19] 田柳.华蟾素胶囊辅助治疗晚期乳腺癌疗效及耐受性观察[J].西南国防医药,2017,27(11):1173-1175.
[20] 邓爽,冯国斌,徐久东,等.华蟾素胶囊联合含卡培他滨基础方案治疗晚期乳腺癌疗效及耐受性观察[J].药学与临床研究,2017,25(5):439-443.
[21] 马传栋,步晓秋,王忠锐,等.含脂质体阿霉素方案在乳腺癌术后辅助化疗中的安全性评价[J].临床肿瘤学杂志,2017,22(7):642-645.
[22] 律慧敏,张梦玮,牛李敏,等.国产多西他赛单药治疗晚期乳腺癌的疗效及安全性[J].山东大学学报(医学版),2018,56(1):45-49.
[23] 沈刚,沈文香.多西他赛联合噻替哌治疗对乳腺癌组织中上皮间质转化分子标志物及Beclin 1表达的影响[J].中国妇幼保健,2017,32(18):4536-4539.
[24] 吴旦平,张红丹,汪波,等.PEG-rhG-CSF注射液对乳腺癌术后化疗致中性粒细胞减少的防治效果[J].重庆医学,2018,47(4):546-548.
[25] 陈喜梅,蔡亚飞,吕转,等.重组人粒细胞集落刺激因子在乳腺癌化疗后应用的临床分析[J].中国实用医刊,2017,44(10):42-45.
[26] 石远凯,许建萍,吴昌平,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少症的多中心上市后临床研究[J].中国肿瘤临床,2017,44(14):679-684.
[27] 徐兵河,田富国,喻璟瑞,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅲ期临床研究[J].中华肿瘤杂志,2016,38(1):23-27.
[28] 邓建良,姚强,张云雷,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞计数减少的临床观察[J].临床内科杂志,2017,34(4):268-270.
[29] 董莉.地榆升白片治疗儿童感染相关粒细胞减少症疗效观察[J].实用中医药杂志,2016,32(10):1010-1011.
[30] 陈君,汪川.地榆升白片治疗儿童中性粒细胞减少症180例疗效观察[J].中国社区医师,2017,33(29):77-79.
[31] 赵泽丰,何希瑞,张强,等.地榆升白片治疗肿瘤化疗后引起的白细胞减少Meta分析[J].西北药学杂志,2017,32(5):648-652.
[32] 刘纯一,胡新彦,徐立霞,等.地榆升白片联合重组人粒细胞刺激因子治疗癌症相关性乏力的临床分析[J].中国生化药物杂志,2015(3):98-99.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |